The Development And Characterization Of Heparin-Conjugated Fibrin Hydrogel With Incapsulated Mesenchimal Stem Cells And Growth Factors
Main Article Content
Authors
M.A. Sarsenova
National Center for Biotechnology, Kurgalzhin road, 13/5, Nur-Sultan, 010000, Kazakhstan
Department of Medicine, School of Medicine, Nazarbayev University, 5/1, Kerey, Zhanibek Handar str., Nur-Sultan, 010000, Kazakhstan
A.S. Issabekova
National Center for Biotechnology, Kurgalzhin road, 13/5, Nur-Sultan, 010000, Kazakhstan
M.R. Karzhauov
National Center for Biotechnology, Kurgalzhin road, 13/5, Nur-Sultan, 010000, Kazakhstan
G.K. Kudaibergen
National Center for Biotechnology, Kurgalzhin road, 13/5, Nur-Sultan, 010000, Kazakhstan
M.S. Zhunussova
National Center for Biotechnology, Kurgalzhin road, 13/5, Nur-Sultan, 010000, Kazakhstan
V.B. Ogay
National Center for Biotechnology, Kurgalzhin road, 13/5, Nur-Sultan, 010000, Kazakhstan
Abstract
Currently, one of the major focuses in regenerative medicine is the development and implementation into practice of composite biomaterials with chondro- and osteoinductive properties, which include human stem cells and growth factors. Heparin-conjugated fibrinogen was obtained using the carbodiimide method, which was further used to create heparin-conjugated fibrin hydrogels (HCFH). As a result of this work, two types of HCFH were obtained: a hydrogel with encapsulated mesenchymal stem cells (MSC) and a hydrogel with TGF-β1 and BMP-4 growth factors. It has been found that synovial MSCs retain viability after encapsulation in HCFH, which indicates that the developed hydrogel is biocompatible and does not have toxic effect to the cells. The results of enzyme-linked immunosorbent assay on the kinetics of BMP-4 and TGF-β1 release from HCFH showed that the developed hydrogel is able to retain BMP-4 and TGF-β1. The kinetics of release from HCFH into phosphate buffer was significantly slower compared to fibrin hydrogel.
Keywords
heparin-conjugated fibrin hydrogel, mesenchymal stem cells, growth factors TGF-β1 and BMP-4.
Article Details
References
Newman A. Articular cartilage repair. American Journal of Sports Medicine, 1998, vol. 26 no. 2, pp. 309-324. Crossref
Serra R., Johnson M., Filvaroff EH., et al. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. Journal of Cell Biology, 1997, vol. 139 no. 2, pp. 541-552. Crossref
Dünker N., Schmitt K., Krieglstein K. TGF-beta is required for programmed cell death in interdigital webs of the developing mouse limb. Mechanisms of Development, 2002, vol. 113, no. 2, pp. 111-120. Crossref
Ahmed T., Giulivi A., Griffith M., et al. Fibrin glues in combination with mesenchymal stem cells to develop a tissue-engineered cartilage substitute. Tissue Engineering. Part A, 2011, vol. 17, no. 3-4, pp. 323-335. Crossref
Yang H.S., La WG., Bhang S.H., et al. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Engineering. Part A, 2010, vol. 16 no. 4, pp. 1225-1233. Crossref
De Bari C., Dell'Accio F., Tylzanowski P., et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis and Rheumatism, 2001, vol.44, no. 8, pp. 1928-1942. Crossref<1928::AID-ART331>3.0.CO;2-P
Prech E., Byul'mann F., Affol'ter K. Opredelenie stroeniya organicheskih soedinenij. Tablicy spektral'nyh dannyh / Per. s angl. B. N. Tarasevicha. - Binom. Laboratoriya znanij, 2006, S. 251-318.
Camara J., Satterfield M., Nelson B. Quantitative determination of disaccharide content in digested unfragmented heparin and low molecular weight heparin by direct-infusion electrospray mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2007, vol. 43, no. 5, pp. 1706-1714. Crossref
Chung YI., Tae G., Hong Y.S. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors. Biomaterials, 2006, vol. 27, no. 12, pp. 2621-2626. Crossref
Sundaram M., Qi Y., Shriver Z., Liu, et al. 2003. Rational design of low-molecular weight heparins with improved in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 2003, vol. 100, no. 2, pp. 651-656. Crossref
Sakiyama-Elbert S., Hubbell J. Development of fibrin derivatives for controlled release of heparin-binding growth factors. Journal of Controlled Release: Official Journal of the Controlled Release Society, 2000, vol. 65, no. 3, pp. 389-402. Crossref
Ricard-Blum S., Féraud O., Lortat-Jacob H., et al. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. Journal of Biological Chemistry, 2004, vol. 279 no. 4, pp. 2927-2936. Crossref
Saksela O., Moscatelli D., Sommer A., et al. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. Journal of Cell Biology, 1998, vol. 107, no. 2, pp. 743-751. Crossref